For the past two decades the Queensland Parkinson’s Project has supported all research at the Griffith Institute for Drug Discovery by collecting essential basic information as well as biological samples from over 4000 volunteers.
This information has been used to identify essential factors in the development and progression of Parkinson’s disease. Genetic information from volunteers has also been in large population genetic analyses assessing and discovering risk factors for disease. Families enrolled in the QPP have also improved our understanding of the very rare genetic forms of disease.
Findings from the many studies have been published in peer- reviewed scientific journals or presented at (inter)national conferences. We also encourage our researchers to contribute their knowledge at community events.
Journal: Traffic, 15(2), 230-44 (2014)
Authors: Follett J, Norwood SJ, Hamilton NA, Mellick GD, et al.
Title: The Vps35 D620N mutation linked to Parkinson's disease disrupts the cargo sorting function of retromer.
Summary : This study outlines functional implications of a newly identified PD-causing mutation in a rare genetic form of Parkinson’s disease.
Journal: PLOS ONE 11(4), e0154544 (2016)
Authors: Murtaza M, Shan J, Matigian N, et al. Mellick GD.
Title: Rotenone susceptibility phenotype in olfactory derived patient cells as a model of idiopathic Parkinson's disease.
Summary : This study describes our team’s human olfactory neurosphere-derived cell model (nasal cells) of Parkinson's disease.
Journal: PLOS ONE 10(5), e0128030 (2015)
Authors: Todorovic M, Newman J, Shan J, Bentley S, Wood SA, Silburn PA, Mellick GD.
Title: Comprehensive assessment of genetic sequence variants in the antioxidant 'master regulator' Nrf2 in idiopathic Parkinson's disease
Summary: This is a paper that describes the demographic characteristics of the current QPP cohort and reveals an association between Nrf2 (a protein associated with oxidative stress) variants and disease risk and altered onset age.
The Mellick team is part of a global initiative—the Genetic Epidemiology of Parkinson's Disease (GEoPD)—with more than 30 members worldwide collaborating together to find the causes and cures for this disease. Importantly, the consortium is dedicated to promoting education, scientific research and translational development in Parkinson’s disease.
Funding to the Mellick team has been gratefully received from a number of sources, including:
- National Health and Medical Research Council (NHMRC)
- Clem Jones Foundation
- AEGIUM Foundation
- Parkinson's Queensland
- Michael J Fox Foundation.
Funding and donations are vital to this research, as identifying the causes and discovering new treatments are lengthy, costly and complex processes.